4//SEC Filing
Baldry Mark 4
Accession 0001628280-23-036466
CIK 0001501697other
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 5:00 PM ET
Size
4.9 KB
Accession
0001628280-23-036466
Insider Transaction Report
Form 4
Baldry Mark
Chief Commercial Officer
Transactions
- Award
Common Stock
2023-10-31+34,947→ 34,947 total
Footnotes (1)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.
Documents
Issuer
X4 Pharmaceuticals, Inc
CIK 0001501697
Entity typeother
Related Parties
1- filerCIK 0001644137
Filing Metadata
- Form type
- 4
- Filed
- Nov 1, 8:00 PM ET
- Accepted
- Nov 2, 5:00 PM ET
- Size
- 4.9 KB